Principal Financial Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-33,749
| Closed | -$115K | – | 2378 |
|
|
2018
Q3 | $115K | Buy |
33,749
+4,106
| +14% | +$14.8K | ﹤0.01% | 2223 |
|
|
2018
Q2 | $111K | Sell |
29,643
-1,864
| -6% | -$9.07K | ﹤0.01% | 2218 |
|
|
2018
Q1 | $129K | Buy |
31,507
+183
| +0.6% | +$852 | ﹤0.01% | 2141 |
|
|
2017
Q4 | $145K | Buy |
31,324
+18,566
| +146% | +$102K | ﹤0.01% | 2165 |
|
|
2017
Q3 | $91K | Sell |
12,758
-2,001
| -14% | -$14.4K | ﹤0.01% | 2145 |
|
|
2017
Q2 | $107K | Buy |
14,759
+590
| +4% | +$3.69K | ﹤0.01% | 2179 |
|
|
2017
Q1 | $87K | Hold |
14,169
| – | – | ﹤0.01% | 2150 |
|
|
2016
Q4 | $83K | Hold |
14,169
| – | – | ﹤0.01% | 2174 |
|
|
2016
Q3 | $75K | Buy |
14,169
+276
| +2% | +$1.49K | ﹤0.01% | 2124 |
|
|
2016
Q2 | $92K | Sell |
13,893
-4,473
| -24% | -$25K | ﹤0.01% | 2090 |
|
|
2016
Q1 | $86K | Buy |
18,366
+839
| +5% | +$3.35K | ﹤0.01% | 2096 |
|
|
2015
Q4 | $89K | Hold |
17,527
| – | – | ﹤0.01% | 2116 |
|
|
2015
Q3 | $62K | Buy |
17,527
+1,904
| +12% | +$12.8K | ﹤0.01% | 2122 |
|
|
2015
Q2 | $156K | Sell |
15,623
-3,120
| -17% | -$33.5K | ﹤0.01% | 2080 |
|
|
2015
Q1 | $238K | Buy |
18,743
+3,977
| +27% | +$51.1K | ﹤0.01% | 1983 |
|
|
2014
Q4 | $209K | Sell |
14,766
-4,110
| -22% | -$63.7K | ﹤0.01% | 2028 |
|
|
2014
Q3 | $260K | Sell |
18,876
-226,900
| -92% | -$3.47M | ﹤0.01% | 1965 |
|
|
2014
Q2 | $3.78M | Sell |
245,776
-22,446
| -8% | -$318K | 0.01% | 1518 |
|
|
2014
Q1 | $4.57M | Sell |
268,222
-353
| -0.1% | -$5.33K | 0.01% | 1411 |
|
|
2013
Q4 | $3.48M | Sell |
268,575
-140,300
| -34% | -$1.68M | 0.01% | 1534 |
|
|
2013
Q3 | $4.13M | Sell |
408,875
-1,761
| -0.4% | -$15.7K | 0.01% | 1391 |
|
|
2013
Q2 | $3.07M | Buy |
+410,636
| New | +$3.21M | 0.01% | 1463 |
|
Principal Financial Group's KERX Position: Q4 2018 in Review
Principal Financial Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 33,749 shares — an estimated $115K sold.
Principal Financial Group first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $4.57M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Principal Financial Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Principal Financial Group sold 33,749 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $115K.
- Principal Financial Group first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Principal Financial Group's Keryx Biopharmaceuticals Inc position peaked at $4.57M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Principal Financial Group's 13F filing for Q4 2018, filed 14 Feb 2019.